Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)
| Autor: | Suner, A., Aydin, D., Bekir Hacioglu, Dogu, G. G., Imamoglu, G. I., Menekse, S., Pilanci, K. N., Yazici, O. K., Koca, D., Karaagac, M., Akyol, M., Akman, T., Ergen, S., Avci, N., Kacan, T., Bozkurt, O., Kefeli, U., Urakci, Z., Araz, M., Arpaci, E., Harputlu, H., Sevinc, A. |
|---|---|
| Přispěvatelé: | [Suner, A. -- Sevinc, A.] Gaziantep Univ, Med Oncol, Gaziantep, Turkey -- [Aydin, D.] Kartal Dr Lotfu Kirdar Training & Res Hosp, Med Oncol, Istanbul, Turkey -- [Hacioglu, M. B.] Trakya Univ, Med Oncol, Edirne, Turkey -- [Dogu, G. G.] Pamukkale Univ, Med Oncol, Denizli, Turkey -- [Imamoglu, G. I.] Diskapi Yildirim Beyazit Training & Res Hosp, Med Oncol, Ankara, Turkey -- [Menekse, S.] Celal Bayar Univ, Med Oncol, Manisa, Turkey -- [Pilanci, K. N.] Istanbul Bilim Univ, Med Oncol, Istanbul, Turkey -- [Yazici, O. K.] Ankara A Yurtaslan Training & Res Hosp, Med Oncol, Ankara, Turkey -- [Koca, D.] Van Istanbul Hosp, Med Oncol, Van, Turkey -- [Karaagac, M.] Necmettin Erbakan Univ, Med Oncol, Konya, Turkey -- [Akyol, M.] Katip Celebi Univ, Med Oncol, Izmir, Turkey -- [Akman, T.] Izmir Tepecik Training & Res Hosp, Med Oncol, Izmir, Turkey -- [Ergen, S.] Bulent Ecevit Univ, Med Oncol, Zonguldak, Turkey -- [Avci, N.] Balikesir Training & Res Hosp, Med Oncol, Balikesir, Turkey -- [Kacan, T.] Cumhuriyet Univ, Med Oncol, Sivas, Turkey -- [Bozkurt, O.] Erciyes Univ, Med Oncol, Kayseri, Turkey -- [Kefeli, U.] Medeniyet Univ, Med Oncol, Istanbul, Turkey -- [Urakci, Z.] Dicle Univ, Med Oncol, Diyarbakir, Turkey -- [Araz, M.] Malatya Training & Res Hosp, Med Oncol, Malatya, Turkey -- [Arpaci, E.] Sakarya Univ, Med Oncol, Sakarya, Turkey -- [Harputlu, H.] Inonu Univ, Med Oncol, Malatya, Turkey, KEFELI, UMUT -- 0000-0001-6126-5377, araz, murat -- 0000-0002-4632-9501 |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
cancer patient prostate adenocarcinoma vomiting castration resistant prostate cancer drug safety peripheral neuropathy Turkey retrospective study very elderly diarrhea thrombocytopenia orchiectomy granulocyte colony stimulating factor taxoid cancer control cancer diagnosis middle aged docetaxel Neoplasm Metastasis cancer survival medical society disease free survival antineoplastic agent Aged 80 and over progression free survival Prostate cancer Cabazitaxel adult prednisolone clinical trial Middle Aged nausea anemia aged Prostatic Neoplasms Castration-Resistant Treatment Outcome anorexia disease severity epidemiology Taxoids Adult overall survival Antineoplastic Agents Article cancer chemotherapy cancer growth Disease-Free Survival neutropenia metastasis Humans Chemotherapy controlled study drug fatality human drug dose reduction survival time metastasis potential Aged Retrospective Studies treatment response cancer center major clinical study mortality human tissue drug efficacy febrile neutropenia multicenter study Turk (people) Toxicities antiandrogen fatigue pathology |
| Zdroj: | Web of Science |
| Popis: | WOS: 000376904300006 PubMed ID: 27097941 OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabazitaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite docetaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m(2) at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hematological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|